This platform specializes in the development and application of organoid and adult stem cell technologies. By harnessing organoid models, we address thyroid disorders through patient-specific disease modeling and drug screening. Our proprietary protocol enables the directed differentiation of induced pluripotent stem cells (iPSCs) into functional cardiomyocyte precursors. The developed adult cardiac stem cell therapeutics show therapeutic potential for cardiovascular diseases, including acute myocardial infarction and heart failure. Supported by expert teams from the Li Ka Shing Faculty of Medicine, The University of Hong Kong, and leveraging extensive clinical networks, we accelerate clinical translation through GMP-compliant stem cell production and IND-enabling studies for cellular therapeutics.
Cardiovascular diseases are the leading global cause of mortality, with heart failure representing the end-stage manifestation of cardiovascular and cerebrovascular diseases. Current treatment options for heart failure remain limited. Transplantation of cardiac progenitor cells into damaged myocardial tissue can promote myocardial regeneration and improve cardiac function. The large-scale production of cardiac progenitor cells offers new hope for cell-based therapies targeting heart failure.
Refractory thyroid cancers exhibit significant prognostic heterogeneity across molecular subtypes, necessitating stratified diagnosis to accurately predict disease progression and recurrence risk. Key molecular subtypes include BRAF-mutant and RAS-mutant variants. Early recurrence monitoring is achieved through genetic mutation profiling combined with blood tests, imaging, and liquid biopsy techniques. Organoid culture systems recapitulate the primary tumor microenvironment, enabling drug sensitivity testing and development of personalized treatment regimens.
All Contents ©2025 AAAR. All Rights Reserved.
